来源：滚动播报 摩根大通将礼来目标价从1150美元上调至1300美元。 ...

Group 1: Insurance Sector - Insurance stocks are experiencing significant declines, with China Life (02628) down 3.75%, New China Life (01336) down 3.28%, and China Pacific Insurance (02601) down 2.74%. The government plans to issue approximately 200 billion yuan in special bonds to inject capital into major insurance companies, marking the first time this method will be used for insurance firms in China [1] Group 2: Logistics and Delivery - ZTO Express (02057) has seen an increase of over 2.3%. The company estimates that its total revenue for 2025 will be between 48.5 billion yuan and 50 billion yuan, representing a growth of approximately 9.5% to 12.9% compared to 44.2807 billion yuan in 2024 [1] Group 3: Biotechnology - Innovent Biologics (09969) has risen over 4%, with a current increase of 3.25%. The company anticipates achieving revenue of 2.37 billion yuan in 2025, a year-on-year growth of approximately 134%, and expects to turn a profit with a net profit of around 630 million yuan [1] Group 4: Coal Sector - Coal stocks are generally declining, with Yancoal Australia (03668) down 6.63%, Shougang Resources (00639) down 7.83%, and China Shenhua (01088) down 2.47%. This decline follows reports that the Indonesian government has proposed a production cut plan, leading to a 40% to 70% reduction in production quotas for major miners [2] Group 5: Medical Devices - GigaGen (02367) has increased over 8%, currently up 4.11%. The company recently announced that its "recombinant type I α1 collagen and sodium hyaluronate composite solution" has been approved as a medical device, marking a significant milestone as the first product of its kind for improving facial smoothness [2] Group 6: Semiconductor Sector - Semiconductor stocks are all declining, with Hua Hong Semiconductor (01347) down 5.91% and SMIC (00981) down 3.49%. This follows a significant drop in AMD's stock price by 17.31% after its fourth-quarter report indicated that while revenue exceeded expectations, the guidance for the first quarter was below market expectations [3] Group 7: Restaurant Sector - Restaurant stocks are performing well, with Yum China (09987) up 8.41% and Haidilao (06862) up 2.69%. The restaurant industry has shown signs of recovery, with retail sales in the sector growing by 3.8%, 3.2%, and 2.2% year-on-year in the last quarter of 2025, significantly outpacing overall retail growth [3] Group 8: Consumer Goods - Miniso (09896) has risen over 5.1% after announcing its partnership with the Central Radio and Television Station for the 2026 Spring Festival Gala. This collaboration is seen as a significant marketing move to elevate the brand's visibility in the mainstream market [4] Group 9: Gold Sector - Gold stocks are declining, with China Gold International (02099) down 6.8% and Zijin Mining (02899) down 6.29%. Recent volatility in the international gold market has been noted, with expectations that geopolitical tensions and liquidity easing by the Federal Reserve may drive gold prices higher [4] Group 10: Cryptocurrency - Cryptocurrency ETFs and related stocks are continuing to decline, with significant drops in prices, including Bitcoin falling below $72,000 for the first time in 15 months. The price has decreased by over 42% from its peak last October [5] Group 11: US Market Highlights - Boston Scientific (BSX.US) fell 17.59% after providing lower-than-expected guidance for fiscal year 2026. The company expects adjusted earnings per share to be between $3.43 and $3.49, slightly below analyst expectations [6] - Solar stocks surged, with Enphase Energy (ENPH.US) rising 38.6% following reports of interest from Elon Musk's teams in the Chinese solar supply chain [6]

这两个适应证合计起来，替尔泊肽2025年全年销售额365.07亿美元（折合人民币2534.24亿元），超过诺 和诺德司美格鲁肽2025年销售额（361亿美元），成为2025年全球销售额最大的药品。 在2024年，全球的药王还是默沙东的肿瘤药物K药物，后者目前暂居全球药品销售额第三位置。 在替尔泊肽的带动之下，礼来全年总营收达到651.79亿美元，按固定汇率CER计算同比增长44%，净利 润206.4亿美元，同比增长95%。礼来预计2026年度总营收将达到800亿至830亿美元。 回顾GLP-1赛道，诺和诺德司美格鲁肽在减肥药适应证上的开发成功，带火了整个GLP-1赛道开发火 热。作为GLP-1/GIP双靶点药物的替尔泊肽，虽然后来居上，但相比司美格鲁肽是GLP-1单靶点药物， 展现出更优的减重效果。 2026.02.05 本文字数：915，阅读时长大约1.5分钟 作者 |第一财经 林志吟 全球年度药王尘埃落定。 2月4日，礼来发布的2025年财报显示，公司的"明星单品"替尔泊肽降糖适应证产品Mounjaro全年销售额 达229.65亿美元，同比增长99%，持续抢占全球糖尿病用药市场份额；减重适应证产品Zepb ...

2026.02. 05 本文字数：915，阅读时长大约1.5分钟 作者 | 第一财经 林志吟 在替尔泊肽的带动之下，礼来全年总营收达到651.79亿美元，按固定汇率CER计算同比增长44%，净利润206.4亿美元，同比增长95%。礼来预计2026年 度总营收将达到800亿至830亿美元。 回顾GLP-1赛道，诺和诺德司美格鲁肽在减肥药适应证上的开发成功，带火了整个GLP-1赛道开发火热。作为GLP-1/GIP双靶点药物的替尔泊肽，虽然 后来居上，但相比司美格鲁肽是GLP-1单靶点药物，展现出更优的减重效果。 司美格鲁肽减肥适应证在全球上市后，曾一度受制于产能供应紧张挑战。而礼来的替尔泊肽的开发到生产，背后有中国企业赋能身影。 有分析指出，礼来在应对GLP-1类药物（如替尔泊肽）巨大的市场需求时，采取了"内部扩产+外部合作"的策略。作为医药外包公司，中国企业药明康德 在全球多肽和寡核苷酸（TIDES）领域产能占据优势，该公司也是礼来的重要合作伙伴。 而药明康德在TIDES业务上的增长，与全球GLP-1市场需求高度相关。从药明康德的财报看，2025年前三季度，公司的TIDES业务收入达到78.4亿元， 同比增长1 ...

全球年度药王尘埃落定。 2月4日，礼来发布的2025年财报显示，公司的"明星单品"替尔泊肽降糖适应证产品Mounjaro全年销售额 达229.65亿美元，同比增长99%，持续抢占全球糖尿病用药市场份额；减重适应证产品Zepbound全年销 售额135.42亿美元，同比增长175%。 这两个适应证合计起来，替尔泊肽2025年全年销售额365.07亿美元（折合人民币2534.24亿元），超过诺 和诺德司美格鲁肽2025年销售额（361亿美元），成为2025年全球销售额最大的药品。 回顾GLP-1赛道，诺和诺德司美格鲁肽在减肥药适应证上的开发成功，带火了整个GLP-1赛道开发火 热。作为GLP-1/GIP双靶点药物的替尔泊肽，虽然后来居上，但相比司美格鲁肽是GLP-1单靶点药物， 展现出更优的减重效果。 司美格鲁肽减肥适应证在全球上市后，曾一度受制于产能供应紧张挑战。而礼来的替尔泊肽的开发到生 产，背后有中国企业赋能身影。 有分析指出，礼来在应对GLP-1类药物（如替尔泊肽）巨大的市场需求时，采取了"内部扩产+外部合 作"的策略。作为医药外包公司，中国企业药明康德在全球多肽和寡核苷酸（TIDES）领域产能占据优 势 ...

截至2026年2月5日09:45，创新药ETF天弘(517380)成交494.51万元。跟踪的恒生沪深港创新药精选50指数(HSSSHID)上涨 0.11%，成分股通化东宝上涨2.64%，凯莱英上涨2.47%，凯莱英上涨2.33%，药明康德上涨2.29%，药明康德上涨2.10%。 截至2月4日，创新药ETF天弘(517380)近20个交易日合计"吸金"3.95亿元。 【产品亮点】 创新药ETF天弘(517380)横跨沪港深三地市场，精选50只头部创新药企业，4成港股搭配6成A股，全面覆盖生物制品、化学 制药等核心领域，实现跨市场布局。 【相关产品】 创新药ETF天弘(517380)，对应场外联接基金(A类：014564；C类：014565)。 减肥药需求持续旺盛，礼来周三公布的第四季度营收同比大增43%至192.9亿美元，调整后每股收益为7.54美元，均超出市 场预期。公司预计2026年全年营收800亿至830亿美元，调整后每股收益为33.50至35美元，也均高于市场预期。 其中，Mounjaro和Zepbound两款减肥药销售额超过116亿美元，占总营收的60%以上。此外，礼来预计2026年全年营收将在 8 ...

Group 1 - Alphabet's Q4 revenue reached $113.83 billion, a year-on-year increase of 18%, with Google Cloud revenue at $17.66 billion, up 48% [2] - Nvidia plans to invest $20 billion in OpenAI, potentially its largest single investment, and aims to participate in another funding round before OpenAI's IPO [2] - Eli Lilly reported Q4 revenue of $19.292 billion, a 43% increase year-on-year, with net profit rising 50% to $6.636 billion [2] Group 2 - Alibaba's Jack Ma was seen at the company's headquarters focusing on AI business development, raising market interest in Alibaba's AI strategy [4] - JinkoSolar announced a stock price deviation of 30% over three trading days, clarifying that it has no undisclosed major information and remains focused on ground photovoltaic business [4] - China Shipbuilding Defense signed contracts for 16 box ship constructions valued between $736 million and $896 million, indicating strong competitiveness in shipbuilding [4] Group 3 - Yum China reported Q4 revenue of $2.82 billion, an 8.8% year-on-year increase, with adjusted EPS at $0.4, up from $0.3 [5] - Hong Kong Stock Exchange's CEO stated that the IPO market is not facing a "logjam," with sufficient funds available for new listings [5] - TSMC plans to produce 3nm chips in Kumamoto, Japan, enhancing its global competitiveness in advanced manufacturing [6] Group 4 - Apple partnered with Alphabet to use it as its preferred cloud service provider, with plans to release new products in 2026 [8] - Amazon's AI assistant Alexa+ is now available to all U.S. users, with plans to invest in OpenAI and accelerate film production using AI [8] - Tesla's Shanghai factory delivered 69,129 vehicles in January, a 9% year-on-year increase, despite a significant drop in sales in the UK market [8] Group 5 - Samsung Electronics' market value surpassed 1 trillion KRW (approximately $688 billion), benefiting from a super cycle in memory chips [11] - Toyota raised its global vehicle production target for 2028 to 11.3 million units, a 10% increase from 2026 [11] - SK Hynix announced record performance bonuses for employees, reflecting strong market conditions and rising NAND prices [11] Group 6 - Amundi plans to reduce exposure to U.S. dollar assets due to concerns over U.S. policy changes, suggesting a shift towards European and emerging markets [14] - Nestlé's CEO plans to restructure the company, focusing on core businesses and divesting non-core assets to boost growth [14] - BMW Group announced plans to launch around 20 new models by 2026, emphasizing electric vehicle development and partnerships [14]

美股三大指数周三收盘涨跌不一，道指涨0.53%，纳指跌1.51%，标普500指数跌0.51%，热门科技股普 遍下跌，AMD跌超17%，英伟达、特斯拉、博通、Meta跌超3%。半导体设备与材料、存储概念股、加 密矿企跌幅居前，闪迪跌近16%，美光科技跌超9%。减肥药概念股、住宅地产涨幅居前，礼来涨超 10%，安进涨超8%。纳斯达克中国金龙指数收跌1.95%，热门中概股普跌，哔哩哔哩跌超6%，百度跌 超4%，阿里巴巴。蔚来、小鹏汽车跌超2%，理想汽车、霸王茶姬涨超1%。 0:00 ...

来源：滚动播报 礼来的替尔泊肽的2025年全年收入超过诺和诺德的司美格鲁肽，提前锁定2025年全球"药王"位置。当地 时间2月4日，美国礼来公司（LLY.US）发布2025年第四季度财报以及2025年全年财报。公司第四季度 营收192.9亿美元，同比增长43%，高于分析师预期；全年总营收达651.79亿美元，按固定汇率CER计算 同比增长44%，净利润206.4亿美元，同比增长95%。 ...

"诺和诺德在2025年依然稳居GLP-1领域龙头，但增速放缓与政策压力显现，未来需在减重市场巩固优 势的同时，加快口服剂型和新兴适应症的布局。"上述分析师认为，全球竞争将呈现"疗效+价格+渠 道"三维博弈，礼来的替尔泊肽是诺和诺德司美格鲁肽最有力的挑战者，而中国企业的崛起可能在中期 改变市场格局。 2月3日，诺和诺德发布2025年财报。数据显示，诺和诺德全年营收3090.64亿丹麦克朗（约合489亿美 元），同比增长6%，净利润1024.34亿丹麦克朗（约合162亿美元），同比增长1%。其中，司美格鲁肽 作为"王牌单品"贡献了361亿美元销售额，同比增长超过10%。 有券商医药行业分析师对21世纪经济报道记者表示，整体来看，诺和诺德在全球糖尿病及肥胖治疗领域 依旧保持领先，但增速较过去几年有所放缓，显示政策环境对高价创新药的盈利模式构成挑战。 例如，替尔泊肽前三季度销售额248亿美元，与司美格鲁肽全年361亿美元的差距正快速缩小。2025年， 全球"药王"究竟花落谁家？一场围绕减重质量、给药方式和全球市场的新战役已经打响。 "王牌"产品成增长引擎 一直以来，各大跨国药企纷纷积极进行产品布局，力图凭借强大的研发 ...